ABSTRACT

This invention relates to the use of JAK1 selective inhibitors, particularly pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine derivatives, in the manufacture of medicaments for treating myelodysplastic syndromes (MDS).

5